[Evaluation of health effect among occupational population exposed to nano-titanium dioxide: a cross-sectional study]

Toxicokinetics, dose-response, and risk assessment of nanomaterials: Methodology, challenges, and future perspectives

The rapid growth of nanomaterial applications has raised safety concerns for human health. A number of studies have been conducted to assess the toxicokinetics, toxicology, dose-response, and risk assessment of different nanomaterials using in vitro and in vivo animal and human models. However, current studies cannot meet the demand for efficient assessment of toxicokinetics, dose-response relationships, or the toxicological risk arising from the rapidly increasing number of newly synthesized nanomaterials. In this article, we review the methods for conducting toxicokinetics, hazard identification, dose-response, exposure, and risk assessment studies of nanomaterials, identify the knowledge gaps, and discuss the challenges remaining. We provide the rationale behind the appropriate design of nanomaterial plasma toxicokinetic and tissue distribution studies, including caveats on the interpretation and correlation of in vitro and in vivo toxicology studies. The potential of using physiologically based pharmacokinetic (PBPK) models to extrapolate toxicokinetic and toxicity findings from in vitro to in vivo and from animals to humans is discussed, and the knowledge gaps of PBPK modeling for nanomaterials are identified. While challenges still exist, there has been progress in the toxicokinetics, hazard identification, and risk assessment of nanomaterials in the past two decades. Recent advancements in the field are highlighted with relevant examples. We also share latest guidelines as well as our perspectives on future studies needed to characterize the toxicokinetics, toxicity, and dose-response relationship in support of nanomaterial risk assessment. This article is categorized under: Toxicology and Regulatory Issues in Nanomedicine > Toxicology of Nanomaterials Toxicology and Regulatory Issues in Nanomedicine > Regulatory and Policy Issues in Nanomedicine.

Blood toxic metals and hemoglobin levels in Mexican children

Metal toxicity can cause hematologic abnormalities and hemolysis. To evaluate the relationship of anemia with metal contamination in children, the following elements were quantified in dry blood: silicon, chromium, lead, titanium, vanadium, nickel, arsenic, manganese, and cadmium. A total of 88 samples of anemic children and 208 of non-anemic children aged 6-12 years were analyzed. Lead (35.1%), chromium (24.3%), vanadium (24.3%), nickel (45.6%), and silicon (48.6%) were identified in the samples, with titanium only detected in anemic children. The average level of arsenic was higher in anemic than non-anemic children (0.041 ± 0.11 wt% vs 0.014 ± 0.05 wt%, p < 0.05) and correlated with the concentration of hemoglobin (r = -0.441, p < 0.01). In conclusion, heavy metals, which confer a health risk, were detected in the dry blood of the children evaluated, and the levels of arsenic and titanium were found to be related to anemia.